




Distribution of Propensity Scores




Raw Treated




Matched Treated





Raw Control



Matched Control







Supplementary Table 1. Univariate and multivariate analyses for overall survival in the study population

Characteristics		3-year OS (%)	Univariate analysis ^a	Multivariate analysis ^b	HR (95% CI)
Age at diagnosis			<0.001	<0.001	1.02 (1.02-1.02)
Race	White/others	60.4	<0.001	<0.001	1
	Black	45.1			1.35 (1.20-1.52)
T stage	1	66.9	<0.001		1
	2	61.6		0.008	1.23 (1.06-1.43)
	3	56.9		<0.001	1.38 (1.16-1.63)
	4	14.7		<0.001	1.60 (1.36-1.87)
N stage	0-2	59.5	<0.001	<0.001	1
	3	54.4			1.29 (1.16-1.43)
Grade	1-2	68.5	<0.001	<0.001	1
	3-4	49.8			1.46 (1.32-1.62)
Hormone receptor	Negative	39.2	<0.001	<0.001	1
	Positive	65.0			0.50 (0.45-0.56)
HER2 receptor	Negative	54.8	<0.001	<0.001	1
	Positive	68.5			0.48 (0.43-0.54)
Breast operation	Mastectomy	58.3	0.861	-	
	Lumpectomy	57.9			
Chemotherapy	Not done/unknown	54.1	<0.001	<0.001	1
	Done	59.7			0.81 (0.72-0.90)
Radiotherapy	Not done/unknown	54.1	<0.001	<0.001	1
	Done	63.5			0.80 (0.73-0.88)
Bone metastasis	Absent	56.3	0.984	-	
	Present	59.6			
Brain metastasis	Absent	59.3	<0.001	<0.001	1
	Present	30.2			1.98 (1.55-2.52)
Liver metastasis	Absent	61.2	<0.001	<0.001	1
	Present	46.0			1.49 (1.29-1.72)
Lung metastasis	Absent	61.2	<0.001	0.577	1
	Present	48.0			1.03 (0.90-1.18)
No of metastatic site*	0	64.3	<0.001		1
	1	60.4		0.012	1.18 (1.04-1.35)
	2	48.1		<0.001	1.49 (1.21-1.82)
	3-4	29.0		<0.001	1.82 (1.30-2.54)

OS, overall survival; HR, hazard ratio; CI, confidence interval;

*No of metastatic site = bone metastasis + brain metastasis + liver metastasis + lung metastasis

^aP-value by Log-rank test^bP-value by Cox proportional hazard model